Sleep is the foundation of our health, yet over one-third of adults struggle with persistent sleep issues, according to epidemiological surveys. These problems can lead to serious outcomes like cardiovascular diseases, cognitive decline, and mental disorders such as anxiety and depression. Yet current treatments, including cognitive behavioral therapy and medications, often fall short. As traditional therapy may not improve objective sleep measures, like drugs can cause side effects like dependency and lack long-term safety guarantees, there’s growing interest in natural solutions, with research suggesting gut microbiota can influence sleep via the gut-brain axis, secreting compounds like short-chain fatty acids. However, Wecare Probiotics’ latest study, focusing on B. animalis subsp. lactis BLa80, offers hope. The research shows BLa80, taken daily at 10 billion CFU for 8 weeks by healthy adults aged 19-45 with poor sleep quality (PSQI 6-18), reduced time to fall asleep by 22 minutes, halved weekly fatigue frequency, and improved PSQI scores by 1.5 points. It also boosted beneficial gut bacteria like Bifidobacterium and Lactobacillus, supporting better sleep through a healthier microbiome. These promising results offer a potential new avenue for addressing the widespread issue of sleep disorders. While further research is warranted to validate these findings in larger and more diverse populations and to fully elucidate the underlying mechanisms, this study highlights the potential of targeted probiotic interventions as a safe and effective strategy to improve sleep quality and overall well-being. The findings pave the way for future research exploring the role of specific probiotic strains in managing various sleep-related issues and contribute to the growing understanding of the gut-brain axis in human health.
-
0 Comments ·0 Shares · ·
-
Introduction The development of effective probiotics to enhance immune function is an area of growing interest in both scientific research and practical application. This journal entry details the innovative approach taken to create a composite probiotic product aimed at improving immune responses. Technical Field This invention pertains to the field of biotechnology and probiotics, specifically focusing on the development and application of a composite probiotic designed to boost the immune system. The composite probiotic consists of specific strains of Bifidobacterium and Lactobacillus known for their health benefits. Background Probiotics are live microorganisms that provide health benefits when consumed in adequate amounts. They are particularly known for their role in maintaining gut health and enhancing immune responses. The gut microbiota plays a crucial role in immune system function, influencing both local and systemic immunity. However, the effectiveness of probiotics can be significantly enhanced by combining different strains that synergistically boost immune functions. Invention Summary The primary objective of this invention is to provide a composite probiotic that enhances the immune system more effectively than individual strains. The composite probiotic comprises:1. Bifidobacterium animalis subsp. lactis BLa80 (CGMCC No. 15410)2. Lactobacillus rhamnosus LRa05 (CGMCC No. 1.12734)3. Lactobacillus acidophilus LA05 (CGMCC No. 23546) These strains are combined to create a synergistic effect, enhancing their individual immune-boosting properties. The combination has shown superior efficacy in improving various immune parameters compared to any single strain alone. Detailed Description Probiotic Composition The probiotic composition includes specific ratios of BLa80, LRa05, and LA05 strains. The optimal ratio for these strains’ ranges from 1:1:1 to 5:5:5 in terms of live bacterial count. This balanced proportion ensures maximum synergistic effect, promoting significant improvements in immune function. Mechanism of Action The composite probiotic enhances immune function through several mechanisms:1. Increased Antioxidant Levels: The combination significantly elevates liver antioxidant factors, which are crucial for reducing oxidative stress and enhancing overall immune function. 2. Reduced Inflammatory Markers: The probiotic mix lowers serum levels of pro-inflammatory cytokines, contributing to a balanced immune response. 3. Enhanced Immunoglobulin Production: There is a notable increase in serum immunoglobulin levels, including IgG and IgA, which play vital roles in systemic and mucosal immunity, respectively. 4. Upregulation of α-Defensins: The probiotics boost the expression of α-defensins in the small intestine, which are essential for maintaining gut barrier integrity and modulating microbial populations. Applications The composite probiotic can be utilized in various forms, including dietary supplements, functional foods, and pharmaceutical preparations, to enhance immune function. It is particularly beneficial for individuals with weakened immune systems, chronic inflammation, or those seeking to maintain optimal health. Conclusion The development of this composite probiotic represents a significant advancement in the field of immune-enhancing probiotics. By leveraging the synergistic effects of BLa80, LRa05, and LA05 strains, this innovative product offers a promising solution for boosting immune function and promoting overall health.
0 Comments ·0 Shares · · -
Wecare Probiotics Co., Ltd., a leading national high-tech enterprise in the field of probiotics, is pleased to share new insights from a recent meta-analysis conducted by Chinese researchers, which highlights the effectiveness of probiotic and synbiotic supplementation in improving bowel function in adults suffering from constipation. The study, published in Pharmacology and Therapeutics, underscores the potential of probiotics, a core focus of our company's research and development efforts, in enhancing digestive health. The meta-analysis, carried out by researchers from Yancheng Third People’s Hospital, Huazhong University of Science and Technology, and The Affiliated Hospital of Xuzhou Medical University, reviewed 17 randomized controlled trials (RCTs) involving a total of 1,256 adults with functional constipation. The findings revealed that probiotic supplementation significantly increased stool frequency by 0.93 times per week and improved stool consistency, compared to placebo. At Wecare Probiotics Co., Ltd., we understand the importance of a healthy gut microbiome for overall well-being. Our range of probiotic products, including multi-strain formulations, is designed to support digestive health and alleviate symptoms of constipation. The study's findings align with our commitment to providing high-quality probiotics that can make a real difference in people's lives. The research also highlighted the superior efficacy of synbiotics, which are a combination of probiotics and prebiotics, in increasing stool frequency. This is particularly relevant as our company offers innovative synbiotic solutions that cater to the growing demand for holistic gut health products. Furthermore, the study found that while probiotics may not significantly alter the overall diversity of the intestinal flora, they can increase the relative abundance of specific beneficial strains. This is a testament to the safety and targeted effectiveness of probiotic supplementation, which is at the heart of Wecare Probiotics Co., Ltd.'s mission to develop products that support the delicate balance of the gut ecosystem. In conclusion, this new research reinforces the potential of probiotics and synbiotics in managing constipation and improving bowel function. At Wecare Probiotics Co., Ltd., we remain committed to harnessing the power of probiotics to enhance human health and well-being. Our diverse range of products, including probiotic powders, fermented food strains, and probiotic preparations, are designed to meet the needs of various industries and consumers seeking natural, effective solutions for digestive health.
0 Comments ·0 Shares · · -
June 9 marks World Women's Reproductive Health Day, highlighting the significance of prioritizing women's health as a crucial aspect in achieving the "Healthy China" strategy. According to the findings from the "2022 Research and Development Trend Analysis on China's Gynecological Drugs Market Status Quo," gynecological diseases have affected over 65% of the global population, with approximately 40% of Chinese women experiencing varying degrees of reproductive tract infections and other related conditions. Furthermore, genitourinary infections worldwide have surpassed an annual incidence rate of 333 million. Gynecological diseases have a significant impact on the daily lives of women, potentially leading to cervical cancer and other serious conditions. What factors contribute to the development of these diseases? The human vaginal environment is a complex micro-ecosystem consisting of a dynamic balance between probiotics and conditionally pathogenic bacteria in the vagina and urethra. When influenced by various factors, the delicate balance of flora can be disrupted, allowing pathogenic bacteria to invade and trigger bacterial, fungal, and other types of infections. Some common examples of these pathogens include E. coli, Gardnerella, and Candida albicans. Women's Reproductive Health Starts with Bacteria Microprobiotics has introduced a groundbreaking probiotic solution aimed at women's intimate care. Through careful selection of patented and advantageous strains such as Lactobacillus Royale LR08, Lactobacillus Plantarum N13, Lactobacillus Curliforme LCr86, and Lactobacillus Acidophilus LA88, the product aims to enhance the vaginal environment's anti-infective capacity. By improving and rebalancing the healthy vaginal micro-ecology and flora, it effectively promotes women's reproductive health. Relevant research data â— Lactobacillus plantarum N13 has good antagonism against Candida albicans Record table of the ability of Lactobacillus plantarum to inhibit Candida albicans Based on the comparison of 10 Lactobacillus plantarum strains that were more effective in inhibiting Candida albicans, it was found that Lactobacillus plantarum N13 antagonized Candida albicans more. â— Lactobacillus acidophilus LA88 inhibits a variety of vaginal pathogenic bacteria to varying degrees Lactobacillus acidophilus LA88 demonstrated varying degrees of inhibition against a diverse range of vaginal pathogenic bacteria. This was particularly evident in its significant inhibitory effect on aerobic pathogens such as Pseudomonas aeruginosa. Additionally, it displayed efficacy against typical vaginal anaerobic pathogens like Gardnerella vaginalis and Atopobium vaginalis. â— Lactobacillus acidophilus LA88 significantly inhibits pathogenic bacteria in the mouse vagina Determination of vaginal flora in mice colony counting table Lactobacillus acidophilus LA88 was able to significantly inhibit pathogenic bacteria and restore the number of beneficial bacteria in the vagina of mice, and a low concentration of Lactobacillus acidophilus LA88 was able to play a role in the repair of the vaginal environment. â— Lactobacillus curvatus strain LCr86 in combination with Lactobacillus griseus strain LG08 has good inhibition of pathogenic bacteria Concentrations of Candida albicans in the vagina of mice in each group Table Lactobacillus curvatus strain LCr86 was able to be used in combination with Lactobacillus griseus strain LG08 for the prevention and treatment of reproductive tract infections with excellent results. Reinforcing Women's Reproductive Health through Intelligent Manufacturing of Premium Probiotics As a leading raw material supplier of probiotic strains, Wecare Probiotics has launched a probiotic solution for women's intimate care, which adopts patented advantageous strains of bacteria, scientifically compounded into a highly active and stable formula, which can prevent or treat vaginitis, improve the vaginal environment or rebuild a healthy human vaginal environment, and improve women's vaginal infections from the root of the problem, and it can be applied in the fields of food, pharmaceuticals, and daily chemical products. The product can be used in food, pharmaceuticals, daily chemicals and so on. The company has consistently adhered to the quality and technology line from start to finish, with a steadfast focus on probiotic strains of science and technology as well as overcoming bottlenecks in industrialization. It has progressed from small-scale pilot testing to large-scale intelligent manufacturing of efficient equipment, establishing industry-leading production facilities and a robust supply chain system for probiotics. From raw materials to finished product testing, the entire process of product processing can be traced back, ensuring the reliable supply of highly stable and highly active probiotic strain raw materials. The research, production, application, and intelligent manufacturing base off the Wecare Probiotics strain Data source invention patents: 1, A kind of compound bacterial agent for preventing and controlling reproductive tract infection (ZL202210443994.9) 2, A kind of Lactobacillus acidophilus LA88 improving vaginal environment and its culture method and application (ZL202210489858.3) 3, The use of Lactobacillus plantarum N13 in the preparation of drugs for the prevention and treatment of vaginitis or inhibition of pathogenic bacteria (ZL202210791819.9)
0 Comments ·0 Shares · · -
Abstract:This article presents a comprehensive safety evaluation of Bifidobacterium animalis subsp. lactis BLa80, a new probiotic strain with potential applications in the food industry. The safety assessment was conducted through in vitro assays simulating gastrointestinal conditions, genomic analysis, and a 90-day oral toxicity test in rats. The strain demonstrated high survival rates under simulated digestive conditions, showed no hemolytic activity, produced no biogenic amines, and exhibited antibiotic susceptibility. Genomic analysis confirmed the absence of virulence factors, and the in vivo toxicity study revealed no adverse effects. Overall, BLa80 is classified as safe for use as a probiotic. Keywords: Bifidobacterium animalis, probiotics, safety evaluation, toxicity, genomic analysis, gastrointestinal survival. Introduction Probiotics have gained attention for their health benefits, particularly in maintaining gut microflora balance and supporting gastrointestinal health. Bifidobacterium animalis subsp. lactis is widely used in the food industry for its probiotic properties. This study evaluates the safety of the newly developed strain BLa80, focusing on its in vitro and in vivo safety profile, genomic characteristics, and overall suitability for consumption. Materials and Methods l Strain and CultureBifidobacterium animalis subsp. lactis BLa80 was isolated from breast milk and cultured in MRS medium. l In Vitro Gastrointestinal SimulationBLa80 was exposed to artificial gastric fluid at pH 2.5 and intestinal fluid at pH 8.0 to evaluate its survival under simulated human digestive conditions. The survival rate was measured after 2 hours of incubation. l Hemolysis TestHemolytic activity was tested on blood agar plates to assess any potential pathogenicity. Staphylococcus aureus was used as a positive control for β-hemolysis. l Antibiotic SusceptibilityAntibiotic susceptibility of BLa80 was tested against a panel of antibiotics, including ampicillin, clindamycin, and chloramphenicol, following Clinical Laboratory Standards Institute (CLSI) guidelines. l Biogenic Amine ProductionHigh-performance liquid chromatography (HPLC) was used to test for the production of biogenic amines like histamine and tyramine. l Bile Salt Hydrolase ActivityThe strain’s ability to hydrolyze bile salts was tested by cultivating BLa80 on bile salt-supplemented media. l Genomic AnalysisWhole-genome sequencing was performed to assess the presence of virulence factors, antibiotic resistance genes, and metabolic pathways. l 90-Day Oral Toxicity TestRats were administered BLa80 at varying doses for 90 days. The study monitored toxicity, including body weight changes, food consumption, and organ health, to determine the No Observed Adverse Effect Level (NOAEL). l Bacterial Translocation TestA translocation assessment was conducted to check for the movement of BLa80 to other organs, including the heart, liver, and kidneys, after ingestion. Results l Survival in Simulated Digestive FluidsBLa80 exhibited a 99.92% survival rate in artificial intestinal fluid and 91.14% in gastric fluid, indicating strong resilience to digestive conditions. l Absence of Hemolytic ActivityNo hemolysis was observed in BLa80 cultures(B), confirming its non-pathogenic nature. l Antibiotic SensitivityBLa80 was sensitive to all antibiotics tested, with MIC values below resistance thresholds. l No Biogenic Amine ProductionNone of the harmful biogenic amines, such as histamine or tyramine, were detected in the strain. l Bile Salt Hydrolase ActivityBLa80 demonstrated bile salt hydrolase activity, which is beneficial for gut survival and function(A). l Genomic SafetyGenomic sequencing confirmed that BLa80 does not carry any virulence or antibiotic resistance genes, further supporting its safety. l Oral Toxicity ResultsThe 90-day oral toxicity test showed no adverse effects in rats, confirming a NOAEL of 1.76 g/kg for female rats and 1.64 g/kg for male rats. l Bacterial TranslocationNo translocation of BLa80 was detected in any of the tested organs, indicating that the strain does not migrate beyond the gastrointestinal tract. Discussion The safety profile of Bifidobacterium animalis subsp. lactis BLa80 is consistent with established standards for probiotic strains. Its high survival rate in gastrointestinal conditions, lack of hemolysis, and sensitivity to antibiotics all support its classification as safe. Furthermore, the absence of biogenic amine production and translocation, combined with the 90-day toxicity test, provides a robust basis for its use in food products. Conclusion The safety assessment of Bifidobacterium animalis subsp. lactis BLa80 demonstrates that it is suitable for use as a probiotic in the food industry. Further studies can focus on its efficacy and potential health benefits in human clinical trials. References · Hill, C., Guarner, F., Reid, G., et al. (2014). "Expert consensus on probiotics." Nat Rev Gastroenterol Hepatol 11(8): 506–514. · Zhou, J., Shu, Q., Rutherfurd, K., et al. (2000). "Acute oral toxicity and bacterial translocation studies on probiotic strains." Food Chem Toxicol 38(2-3): 153–161.
0 Comments ·0 Shares · ·
